YUHAN USA
Yuhan USA is a global business development arm of Yuhan Corporation. We are exploring collaborative opportunities and seeking partnerships with global academic research centers, biotech startups, and pharmaceutical companies. Our goal is to identify potential therapeutic assets with validated proof-of-concept data for potential equity investment and in-licensing.
Our Licensing Focus
Oncology
Targeted therapy, immunitheraphy
Platform Tech
TPD, tumor / immune cell therapy delivery system, AI / Big data drug discovery
Obesity / Metabolism
Incretin / non-incretin-based therapeutics
Fibrosis
Lung / kidney
Our Investment Focus
Therapeutics and technology that transforms care for patients in the U.S. and global markets.
Strong management teams that are able to focus on the bigger picture and efficiently utilize capital by strategically prioritizing assets for optimal long-term value creation.
Potential for partnerships and collaborations with global pharmaceutical companies, including those in our South Korean network
YUHAN Corporation
Since 1926, Yuhan Corporation has upheld its commitment to transparent management and extensive research, striving to develop innovative drugs that positively impact people. With over 300 scientists at Yuhan Research Institute, we are striving to become a patient-centered global leading pharmaceutical company.
